Oragenics, Inc.
OGENAMEXHealthcareBiotechnology
Previous close
$0.525
−$0.015 · -2.78%
OGEN company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
46
Fair Value
Momentum
25
Weakening
Sentiment
56
Mixed
Risk resilience
30
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteOragenics, Inc. (OGEN) is a U.S.-based biotechnology firm primarily focused on creating treatments for infectious diseases. Among its pipeline assets are two vaccine candidates designed to combat the novel severe acute respiratory syndrome coronavirus (SARS-CoV-2): NT-CoV2-1, an intranasal formulation, and Terra CoV-2, an intramuscular option. Beyond its infectious disease focus, Oragenics also has other experimental treatments under development, including LPT3-04, targeting weight loss, and SMaRT Replacement Therapy, a topical solution aimed at preventing dental cavities. Strategic alliances are also a part of its operations. This includes a licensing deal with Noachis Terra Inc. for patents and biological resources related to pre-fusion coronavirus spike proteins. Additionally, Oragenics is collaborating with Precigen, Inc. and ILH Holdings, Inc. on the advancement and market introduction of MU1140 and its associated compounds. Established in 1996, the company, formerly known as Oragen, Inc., maintains its headquarters in Tampa, Florida.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Janet Huffman
- Listed since
- Feb 25, 2004
- Employees
- 3
Market position
Day range
Current $0.525
52-week range
Current $0.525
- Open
- $0.5312
- Previous close
- $0.54
- Volume
- 55.66K
- 1.29× average
- Average volume
- 43.28K
- Average daily volume
- Market cap
- 2.37M USD
- Beta
- 1.24
- Market reference 1
- 50-day average
- $0.5572
- -5.78% below average
- 200-day average
- $0.7194
- -27.02% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- -2.48M USD
- P/E (TTM)
- -0.15×
- P/B (TTM)
- 0.63×
- P/S (TTM)
- 0×
- EV / EBITDA
- -0×
- Earnings yield
- -582.59%
- Free cash flow yield
- -547310.70%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 0.00%
- Operating margin
- 0.00%
- Net margin
- 0.00%
- Return on equity
- -118.85%
- Return on assets
- -97.76%
- Return on invested capital
- -108.52%
Financial health
- Debt / equity
- 0×
- Current ratio
- 5.64×
Financial statements
Income trends
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 2.39B USD | 4.11M USD | 15.49M USD | 10.07M USD | 10.59M USD |
| Selling, general, and administrative | 6.97B USD | 6.44M USD | 5.45M USD | 4.48M USD | 5.27M USD |
| Operating expenses | 9.36M USD | 10.56M USD | 20.9M USD | 14.42M USD | 15.77M USD |
| Interest income | 182.23K USD | 45.9K USD | 210.39K USD | 135.9K USD | 75.85K USD |
| Interest expense | 785.93K USD | 29.83K USD | 30.59K USD | 15.1K USD | 15.76K USD |
| Depreciation and amortization | 771.44M USD | — | 27.39K USD | 44.67K USD | 41.24K USD |
| Operating income | −9.36M USD | −10.56M USD | −20.9M USD | −14.42M USD | −15.77M USD |
| Net income | −9.84M USD | −10.57M USD | −20.66M USD | −14.29M USD | −15.71M USD |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 88%
- 7 beats, 1 miss, 0 met estimates
- Average EPS surprise
- +65.21%
- 8 comparable reports
- Latest EPS result
- -0.57
- Estimate -90 · Beat by 99.37%
EPS: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Rating distribution
3 ratingsLimited analyst sample: 3 ratings. Interpret the distribution with caution.
Corporate actions
Corporate action history
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jun 3, 2025 | 1:30 | — | — |
Stock split | Jan 23, 2023 | 1:60 | — | — |
Stock split | Jan 22, 2018 | 1:10 | — | — |
Stock split | Sep 28, 2010 | 1:20 | — | — |
Effective Jun 3, 2025
1:30
Effective Jan 23, 2023
1:60
Effective Jan 22, 2018
1:10
Effective Sep 28, 2010
1:20
OGEN peers
Continue in GoAI
Research OGENresearch.disclaimer